RE: News on the way17 Apr 2023 14:06
The big pharma companies, such as GSK, Pfizer, and Moderna, are likely to open a market that will, according to analysts, be ultimately worth over $10 billion a year.
It's a decent new source of revenue, but the challenge will be to find the follow-on treatments that help maintain and expand share of the market.
That's where the likes of Poolbeg come in, providing the blue-chip drug developers with their next vaccine iteration.